|
End-of-day quote
Shanghai S.E.
25/08/2026
|
5-day change | 1st Jan Change | ||
| 18.41 CNY | +6.05% |
|
+2.79% | +4.48% |
| 08-24 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 24.7 | +34.17% | 7 | ||||||
| 58.57 | +79.99% | 16 | ||||||
| 4.606 | +67.85% | 15 | ||||||
| 3,035 | +16.73% | 10 | ||||||
| 33.09 | +39.02% | 12 | ||||||
| 121.52 | +29.55% | 9 | ||||||
| 327.88 | +64.33% | 8 | ||||||
| - | - | 1,415 | +211.15% | 1 | ||||
| 48.83 | +30.92% | 6 | ||||||
| 37.19 | +30.48% | 8 | ||||||
| 86.1 | +38.76% | 10 | ||||||
| 14.86 | +26.27% | 5 | ||||||
| 52.7 | +34.85% | 8 | ||||||
| 1,013.14 | +49.4% | 7 | ||||||
| - | 92.5 | +22.84% | 2 | |||||
| - | 5,100 | +37.84% | 2 | |||||
| Average | 716.61 | +50.89% | 8 | ||||||
| Weighted average by Cap. | 562.84 | +59.21% | 11 |
Select your edition
All financial news and data tailored to specific country editions
